CWA Asset Management Group LLC Boosts Stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

CWA Asset Management Group LLC increased its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 25.5% during the fourth quarter, Holdings Channel.com reports. The firm owned 33,698 shares of the biopharmaceutical company’s stock after purchasing an additional 6,853 shares during the quarter. CWA Asset Management Group LLC’s holdings in Catalyst Pharmaceuticals were worth $703,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently bought and sold shares of the stock. Pacer Advisors Inc. raised its stake in shares of Catalyst Pharmaceuticals by 130,918.8% in the second quarter. Pacer Advisors Inc. now owns 2,967,575 shares of the biopharmaceutical company’s stock worth $45,968,000 after buying an additional 2,965,310 shares during the period. Renaissance Technologies LLC raised its stake in Catalyst Pharmaceuticals by 15.2% during the 2nd quarter. Renaissance Technologies LLC now owns 2,175,727 shares of the biopharmaceutical company’s stock worth $33,702,000 after acquiring an additional 287,300 shares during the period. Jane Street Group LLC lifted its holdings in Catalyst Pharmaceuticals by 245.4% during the third quarter. Jane Street Group LLC now owns 401,908 shares of the biopharmaceutical company’s stock valued at $7,990,000 after purchasing an additional 285,564 shares in the last quarter. Integral Health Asset Management LLC bought a new position in shares of Catalyst Pharmaceuticals in the second quarter worth approximately $4,260,000. Finally, Dimensional Fund Advisors LP increased its stake in shares of Catalyst Pharmaceuticals by 9.6% in the second quarter. Dimensional Fund Advisors LP now owns 3,000,756 shares of the biopharmaceutical company’s stock worth $46,479,000 after purchasing an additional 263,099 shares in the last quarter. 79.22% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

CPRX has been the subject of several recent analyst reports. Stephens assumed coverage on shares of Catalyst Pharmaceuticals in a report on Monday, November 18th. They issued an “overweight” rating and a $35.00 target price for the company. StockNews.com raised Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, January 3rd. HC Wainwright reissued a “buy” rating and set a $30.00 target price on shares of Catalyst Pharmaceuticals in a research note on Friday, November 8th. Finally, Truist Financial upped their price target on Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the stock a “buy” rating in a research note on Monday, November 11th. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $31.14.

Catalyst Pharmaceuticals Price Performance

NASDAQ CPRX opened at $19.53 on Wednesday. Catalyst Pharmaceuticals, Inc. has a 1-year low of $13.12 and a 1-year high of $24.27. The business has a 50 day simple moving average of $21.72 and a two-hundred day simple moving average of $19.86. The stock has a market capitalization of $2.33 billion, a PE ratio of 16.55, a P/E/G ratio of 3.35 and a beta of 0.79.

Insider Activity at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, insider Gary Ingenito sold 12,000 shares of Catalyst Pharmaceuticals stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $22.72, for a total value of $272,640.00. Following the completion of the transaction, the insider now directly owns 51,391 shares of the company’s stock, valued at $1,167,603.52. This trade represents a 18.93 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Steve Miller sold 50,000 shares of the business’s stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $21.93, for a total transaction of $1,096,500.00. Following the completion of the sale, the insider now owns 686,996 shares in the company, valued at approximately $15,065,822.28. This trade represents a 6.78 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 79,500 shares of company stock valued at $1,754,140. 11.00% of the stock is owned by corporate insiders.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.